Adds share move and analyst comment in paragraph 2, CEO quotes in paragraphs 4-5 and 7, background in paragraph 8.
By Dimitri Rhodes
Feb 12 (Reuters) - European chemicals maker dsm-firmenich DSFIR.AS reported fourth-quarter core earnings below market expectations on Thursday, weighed down by adverse currency exchange rates, days after it agreed the long-awaited sale of its animal nutrition and health business.
Shares in the group dropped 8% in early Amsterdam trading after what J.P. Morgan analysts described as a "soft" release.
The company announced a deal to sell the animal nutrition and health unit to private equity firm CVC Capital Partners CVC.AS on Monday, while retaining a 20% stake in the business, marking the final step in its plan to focus fully on consumer-facing fields of nutrition, health and beauty.
"If there's an opportunity for value capturing, we want to be part of that. But it's no longer part of the core strategy for the company," CEO Dimitri de Vreeze told Reuters.
Analysts had on Monday said the 2.2 billion euro ($2.6 billion) value for the unit seemed low. But De Vreeze said the price was fair based on multiples and noted that last year's sale of the feed enzyme unit, previously part of the animal feed business, brought the total proceeds to 3.7 billion euros.
Dsm-firmenich's adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) were 478 million euros in the fourth quarter, including discontinued operations. That fell short of analysts' forecast of 488 million euros in a company-provided consensus.
"We have as a company a sensitivity to the Swiss franc and the U.S. dollar. So one cent on the dollar is around 15 million euros on our bottom line. And for the Swiss franc, one rappen is about 10," de Vreeze said.
The group had lowered its full-year adjusted EBITDA guidance in October to account for negative foreign exchange effects.
It proposed a stable cash dividend of 2.50 euros to be paid from 2025 earnings.
($1 = 0.8425 euros)
(Reporting by Dimitri Rhodes in Gdansk, editing by Milla Nissi-Prussak)
((Dimitri.Rhodes@thomsonreuters.com))